Loncastuximab Tesirine for Follicular Lymphoma (LOTIS-6 Trial)

"Currently, there are 18 ongoing research projects using Loncastuximab Tesirine with 3 of them in their final Phase. The majority of the trials take place in Cleveland, Ohio yet 581 different places have registered for various studies involving Loncastuximab Tesirine."

"Loncastuximab Tesirine is a potent medication for chronic lymphocytic leukemia and it can also be employed to combat relapsed large b-cell lymphoma, multiple lines of systemic treatment, as well as other forms of non-Hodgkin's B-Cell Lymphomas."

"Leveraging our internal evaluation criteria, Power assigned a score of 2 to Loncastuximab Tesirine's safety due to the fact that this is only a Phase 2 trial and has yet to demonstrate efficacy."

"Data hosted on clinicaltrials.gov elucidates that this trial is not presently enlisting volunteers. This research project, which was initially published on November 4th 2021, has most recently been adjusted on July 26th 2022; however, 1737 alternative trials are currently enrolling patients."

"This research study is no longer accepting any new participants. It was created on November 4th 2021 and last modified on July 26th 2022. For those seeking other clinical trials, there are currently 1719 studies recruiting for refractory follicular lymphoma and 18 trials involving Loncastuximab Tesirine actively enrolling patients."

"Since 2014, Loncastuximab Tesirine has been under investigation. The initial test was sponsored by Gilead Sciences and included 50 participants. After the Phase 1 trial success of this drug in 2014, it received its Phase 2 approval. Nowadays there are 18 concurrent trials for Loncastuximab Tesirine taking place in 176 cities over 31 countries worldwide."